ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO482

Kidney Stone Incidence Rate in Patients with ADPKD, 2000-2023

Session Information

Category: Genetic Diseases of the Kidneys

  • 1201 Genetic Diseases of the Kidneys: Cystic

Authors

  • Ostrow, Anna, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
  • You, Zhiying, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
  • Turnbull, David, Intermountain Healthcare, Salt Lake City, Utah, United States
  • Belnap, Tom, Intermountain Healthcare, Salt Lake City, Utah, United States
  • Anand, Sanjiv, Intermountain Healthcare, Salt Lake City, Utah, United States
  • Nazzal, Lama, New York University, New York, New York, United States
  • Li, Huilin, New York University, New York, New York, United States
  • Goldfarb, David S., New York University Grossman School of Medicine, New York, New York, United States
  • Nowak, Kristen L., University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
  • Gitomer, Berenice Y., University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
  • Chonchol, Michel, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Background

The incidence of kidney stone disease (KSD) has increased in the general population in recent times. However, trends in KSD among patients with autosomal dominant polycystic kidney disease (ADPKD) remain poorly understood. Thus, the goal of the current study is to define the incidence of KSD from 2000-2023 according to sex and age in an ADPKD population.

Methods

De-identified data from Intermountain Healthcare, an integrated healthcare delivery system in Utah, was utilized for the study after approval by the respective Institutional Review Boards. Overall, 976 subjects aged ≥ 18 years with an ADPKD diagnosis were included in the study. Among these, 183 had a diagnosis of KSD based on ICD-9 or ICD-10 codes during the observation period. Incidence rates of KSD were calculated per 1000 patient years and summarized by sex across 5-year intervals and by age.

Results

The overall incidence rate of KSD increased from 11.1/1000 patient years between 2000-2004 to 20.3/1000 patient years between 2020-2023. This increase was observed in both male and female patients with a slightly higher incidence in men (23.2/1000 patient years compared to women (18.1/1000 patient years in women) in the period 2020-2013 (Figure 1). The incidence rate of KSD remained fairly constant across age groups.

Conclusion

Similar to the general population, incidence rate of KSD has increased recently among ADPKD patients. As KSD may contribute to the overall morbidity of ADPKD, periodic monitoring of urine stone risk factors in patients with ADPKD should be considered.

Funding

  • NIDDK Support